The stock of ARS Pharmaceuticals Inc (SPRY) has seen a 26.54% increase in the past week, with a 23.43% gain in the past month, and a -32.69% decrease in the past quarter. The volatility ratio for the week is 9.35%, and the volatility levels for the past 30 days are at 6.45% for SPRY.. The simple moving average for the past 20 days is 25.82% for SPRY’s stock, with a -29.71% simple moving average for the past 200 days.

Is It Worth Investing in ARS Pharmaceuticals Inc (NASDAQ: SPRY) Right Now?

while the 36-month beta value is 0.34.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”

The average price point forecasted by analysts for ARS Pharmaceuticals Inc (SPRY) is $8.00, which is $3.47 above the current market price. The public float for SPRY is 40.82M, and currently, short sellers hold a 16.18% ratio of that floaft. The average trading volume of SPRY on November 16, 2023 was 1.34M shares.

SPRY) stock’s latest price update

The stock price of ARS Pharmaceuticals Inc (NASDAQ: SPRY) has jumped by 7.09 compared to previous close of 4.23. Despite this, the company has seen a gain of 26.54% in its stock price over the last five trading days. PennyStocks reported 2023-10-04 that When constructing a watch list of penny stocks, it is wise to closely monitor any legal insider trading activity. Though the rules surrounding insider trades are complex, legal filings by company executives and directors can act like signals for savvy penny stock investors.

SPRY Trading at 2.57% from the 50-Day Moving Average

After a stumble in the market that brought SPRY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.06% of loss for the given period.

Volatility was left at 6.45%, however, over the last 30 days, the volatility rate increased by 9.35%, as shares surge +26.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.62% lower at present.

During the last 5 trading sessions, SPRY rose by +26.54%, which changed the moving average for the period of 200-days by -28.55% in comparison to the 20-day moving average, which settled at $3.65. In addition, ARS Pharmaceuticals Inc saw -46.89% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at SPRY starting from Fitzpatrick Alexander A, who purchase 46,258 shares at the price of $3.78 back on Sep 29. After this action, Fitzpatrick Alexander A now owns 89,227 shares of ARS Pharmaceuticals Inc, valued at $174,994 using the latest closing price.

Fitzpatrick Alexander A, the Chief Legal Officer of ARS Pharmaceuticals Inc, purchase 40,000 shares at $3.62 during a trade that took place back on Sep 28, which means that Fitzpatrick Alexander A is holding 42,969 shares at $144,960 based on the most recent closing price.

Stock Fundamentals for SPRY

Current profitability levels for the company are sitting at:

The net margin for ARS Pharmaceuticals Inc stands at -2635.41. The total capital return value is set at -11.98, while invested capital returns managed to touch -11.72. Equity return is now at value -28.50, with -27.38 for asset returns.

Based on ARS Pharmaceuticals Inc (SPRY), the company’s capital structure generated 0.18 points at debt to equity in total, while total debt to capital is 0.18. Total debt to assets is 0.17, with long-term debt to equity ratio resting at 0.09. Finally, the long-term debt to capital ratio is 0.09.

When we switch over and look at the enterprise to sales, we see a ratio of 100.43, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 2.61 and the total asset turnover is 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 51.01.


In a nutshell, ARS Pharmaceuticals Inc (SPRY) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.